On April 17, 2019 Cell Medica, a leader in next-generation cellular immunotherapies for the treatment of cancer, reported that its collaborators from Baylor College of Medicine and Texas Children’s Hospital will be presenting the latest progress related to its innovative CAR therapy utilizing natural killer T cells (CAR-NKT) at the upcoming 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) April 29 – May 2 in Washington, D.C (Press release, Cell Medica, APR 17, 2019, View Source [SID1234535168]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chris Nowers, Cell Medica’s CEO, said: "Our next-generation CAR-NKT platform combines the unique natural antitumor properties of NKT cells with innovative CAR constructs, enabling the possibility of producing multiple highly tumor-specific therapeutic products. We believe this approach could open up the broad potential of NKT cells to serve as a basis for off-the-shelf cell therapies targeting both solid and hematological tumors. We look forward to the important new updates that our collaborators at Baylor and Texas Children’s Hospital will be sharing at ASGCT (Free ASGCT Whitepaper)."

Details of the three oral presentations:

Harnessing Natural and Engineered Properties of iNKT Cells for Adoptive Cancer Immunotherapy
Presenter: Dr. Leonid Metelitsa, Professor of Pediatrics, Hematology-Oncology, Baylor College of Medicine
Session Title: NK cells Versus iNKT cells (Education Session)
Session Date/Time: Monday Apr 29, 2019 1:30 PM – 3:00 PM
Presentation Time: 1:30 PM – 2:00 PM
Room: Georgetown

NKT Cells Co-expressing a GD2-specific Chimeric Antigen Receptor and IL-15 Show Enhanced In Vivo Persistence and Antitumor Activity Against Neuroblastoma
Presenter: Dr. Andras Heczey, Assistant Professor of Pediatrics, Hematology-Oncology, Baylor College of Medicine
Session Title: Oral Abstract Session V
Session Date/Time: Tuesday Apr 30, 2019 8:00 AM – 10:00 AM
Presentation Time: 8:15 AM – 8:30 AM
Final abstract number: 367
Room: Heights Courtyard 3

Development of an Allogeneic Universally Tolerated NKT Cell Platform for Off-the-Shelf Cancer Immunotherapy
Presenter: Dr. Leonid Metelitsa, Professor of Pediatrics, Hematology-Oncology, Baylor College of Medicine
Session title: Cancer Gene Therapy
Session Date/Time: Wednesday May 1, 2019 3:45 PM – 5:30 PM
Presentation Time: 5:00 PM – 5:15 PM
Final abstract number: 682
Room: Monroe

The full abstracts can be accessed at: View Source

– ENDS –

Notes to Editors

About ASGCT (Free ASGCT Whitepaper)

The American Society of Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) Annual Meeting provides an international forum where the latest gene and cell therapy developments are presented and critically discussed. As the leading American conference focusing solely on gene and cell therapy, ASGCT (Free ASGCT Whitepaper)’s annual meeting brings together more than 3,400 professionals including scientists, physicians, and patient advocates.

Find out more at: View Source

Media registration is open at: View Source

About GINAKIT2

GINAKIT2 is a first-in-human, dose escalation evaluation of CMD-501 in children with relapsed or refractory (R/R) high risk neuroblastoma (NCT03294954). Neuroblastomas occur primarily in children and account for 7-10 percent of all pediatric cancers. Ninety percent of patients are younger than 5 years at diagnosis. R/R high risk neuroblastoma is one of the deadliest types of childhood cancer and the current median survival is around 1-3 years. Almost all neuroblastomas express GD2, which is targeted by CMD-501. This study is supported by a grant from Alex’s Lemonade Stand Foundation (ALSF), awarded to Baylor College of Medicine investigators, Drs. Heczey and Metelitsa.

On April 17, 2019 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body’s immune system to fight cancer, reported that the United States Patent and Trademark Office ("USPTO") has issued US Patent No. 10,259,855 (Press release, Anixa Biosciences, APR 17, 2019, View Source [SID1234535167]). This is the first patent covering Anixa’s CAR-T cancer treatment technology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The patent is titled "METHODS AND COMPOSITIONS FOR TREATING CANCER," and the inventors are Drs. Jose Conejo-Garcia and Alfredo Perales-Puchalt. Dr. Conejo-Garcia is the Chair of the Department of Immunology at Moffitt Cancer Center and Dr. Perales-Puchalt is a Senior Postdoctoral Fellow in The Wistar Institute’s Vaccine & Immunotherapy Center. The patent is assigned to The Wistar Institute and Anixa Biosciences’ majority-owned subsidiary, Certainty Therapeutics, Inc. is the exclusive, world-wide licensee.

Dr. Amit Kumar, Anixa’s Chairman, President and CEO, stated, "The claims of this patent were allowed in January of this year as noted in a previous announcement, and we are pleased that this key patent has now issued. Those interested in reviewing the patent can now read the content." Dr. Kumar continued, "This technology takes advantage of specific hormone–hormone receptor biology to address malignancies and may hold promise to be the one of the first successful CAR-T therapies against solid tumors. While our initial focus is the treatment of ovarian cancer, the technology covered by the patent is broad and may also be effective in treating other solid tumors by exploiting an anti-angiogenesis mechanism of action. Anixa and its research and clinical development partner, the Moffitt Cancer Center, hope to file an IND application for this therapy later this year."

On April 17, 2019 Genmab A/S (Nasdaq Copenhagen: GEN) reported that 14 industry sponsored abstracts regarding Genmab programs were accepted for presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place in Chicago from May 31 to June 4, 2019 (Press release, Genmab, APR 17, 2019, View Source [SID1234535166]). The titles of the abstracts are currently available on the ASCO (Free ASCO Whitepaper) iPlanner website, with the full abstracts scheduled to be published on May 15, 2019. A list of accepted industry sponsored abstracts is provided below, and includes ten daratumumab abstracts, two of which were accepted for oral presentations, one abstract on enapotamab vedotin, and two abstracts on tisotumab vedotin (Trial in Progress abstracts).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased that once again a wide selection of abstracts concerning Genmab proprietary and partnered programs was selected for presentation at the prestigious ASCO (Free ASCO Whitepaper) Annual Meeting. We are especially looking forward to the first full presentations of data from the COLUMBA and CASSIOPEIA daratumumab Phase III trials," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. "We are equally excited to begin sharing with the oncology community early data from enapotamab vedotin and ongoing trials in progress for tisotumab vedotin."

Representatives from Genmab will be in attendance at ASCO (Free ASCO Whitepaper), booth #24159.

List of Industry Sponsored Abstracts:

Daratumumab (Submitted by Janssen Biotech, Inc.):
Phase 3 Randomized Study of Daratumumab + Bortezomib/Thalidomide/Dexamethasone (D-VTd) Vs VTd in Transplant-eligible Newly Diagnosed Multiple Myeloma: CASSIOPEIA Part 1 Results – Oral presentation, Sunday, June 2, 10:45 AM – 10:57 PM CDT

Efficacy and Safety of the Randomized, Open-Label, Non-inferiority, Phase 3 Study of Subcutaneous Versus Intravenous Daratumumab Administration in Patients with Relapsed or Refractory Multiple Myeloma: COLUMBA – Oral presentation, Sunday, June 2, 11:09 AM – 11:21 AM CDT

Efficacy of Daratumumab + Bortezomib/Thalidomide/Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma Based on Minimal Residual Disease Status: Analysis of the CASSIOPEIA Trial –Poster presentation, Monday, June 3, 8:00 AM – 11:00 AM CDT

Stem Cell Yield and Transplantation Results from Transplant-eligible Newly Diagnosed Multiple Myeloma Patients Receiving Daratumumab + Bortezomib/Thalidomide/Dexamethasone (D-VTd) in the Phase 3 CASSIOPEIA Study –Poster presentation, Monday, June 3, 8:00 AM – 11:00 AM CDT

Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients with transplant-ineligible newly diagnosed multiple myeloma: MAIA – Poster presentation, Monday, June 3, 8:00 AM – 11:00 AM CDT

Faster and sustained improvement in health-related quality of life for newly diagnosed multiple myeloma patients ineligible for transplant treated with daratumumab, lenalidomide, and dexamethasone (D-Rd) vs Rd alone: MAIA – Poster presentation, Monday, June 3, 8:00 AM – 11:00 AM CDT

Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma based on cytogenetic risk: updated subgroup analysis of CASTOR – Poster presentation, Monday, June 3, 8:00 AM – 11:00 AM CDT

Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma: updated subgroup analysis of POLLUX based on cytogenetic risk – Poster presentation, Monday, June 3, 8:00 AM – 11:00 AM CDT

Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab in patients with transplant-eligible newly diagnosed multiple myeloma: a multicenter, randomized, phase 3 study (PERSEUS) – Poster, Monday, June 3, 8:00 AM – 11:00 AM CDT

Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab in patients with newly diagnosed multiple myeloma for whom transplant is not planned as initial therapy: a multicenter, randomized, phase 3 study (CEPHEUS) – Poster presentation, Monday, June 3, 8:00 AM – 11:00 AM CDT

Tisotumab vedotin (Submitted by Seattle Genetics):
SGNTV-001: Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or
Metastatic Disease in Solid Tumors – Poster presentation, Saturday, June 1, 2019, 8:00 AM – 11:00 AM CDT

Phase 2 Trial of Tisotumab Vedotin in Platinum-Resistant Ovarian Cancer (innovaTV 208) – Poster presentation, Saturday, June 1, 2019, 1:15 PM – 4:15 PM CDT

Enapotamab vedotin:
First-in-human, dose-escalation, phase 1 trial to evaluate safety of anti-Axl antibody–drug conjugate enapotamab vedotin in solid tumors – Poster presentation, Saturday, June 1, 2019, 8:00 AM – 11:00 AM CDT

Ofatumumab (Submitted by Novartis):
Long-term follow-up of previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) treated with ofatumumab and chlorambucil: Final analysis of the phase 3 COMPLEMENT 1 trial –Poster presentation, Monday, June 3, 8:00 AM – 11:00 AM CDT

On April 17, 2019 ImaginAb Inc., a clinical stage immuno-oncology imaging company, reported that it is scheduled to present at the following investor and scientific conferences in April and May 2019 (Press release, ImaginAb, APR 17, 2019, View Source [SID1234535165]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AIM at Melanoma

April 26-28, 2019, Hotel L’Echiquier Opera Paris, 38 Rue De L Echiquier, Paris

Dr. Anna Wu, Founder, and Board Director, and Ivan Plavec, CBO will be attending and making a presentation on ImaginAb at the 26th International Myeloma Working Group meeting in Paris.

Anglo-Nordic Life Science Conference

May 9, 2019, The County Hall, Belvedere Road, London

Ian Wilson, CEO, will be a panelist at the ‘Technologies and Treatments – What’s on the horizon’ discussion at 13.30 BST.

Bio€quity Europe 2019

May 20-21, 2019, Crowne Plaza Fira Center, Barcelona

Ian Wilson, CEO, and Ivan Plavec, CBO, will be attending and hosting meetings.

2019 ASCO (Free ASCO Whitepaper) Annual Meeting

May 31-June 4, 2019, McCormick Place, Chicago

Ian Wilson, CEO, Ivan Plavec, CBO, and Ron Korn CMO, will be attending and hosting meetings.

Inquiries:

ImaginAb

Ian Wilson

Email: [email protected]

Phone: +1 310 645 1211

Optimum Strategic Communications

Mary Clark, Supriya Mathur

Email: [email protected]

Phone: +44 20 3950 9144

On April 17, 2019 OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, and Duke University School of Medicine, reported that they have entered into a collaborative research agreement to evaluate the use of OncoSec’s proprietary TAVOPLUS (enhanced IL-12 DNA-plasmid) in combination or sequence with a HER2-plasmid vaccine administered with OncoSec’s novel intratumoral delivery system (Press release, OncoSec Medical, APR 17, 2019, View Source [SID1234535161]). The research will be led by Herbert Kim Lyerly, M.D., George Barth Geller Professor, Professor of Immunology, Surgery and Pathology at Duke University School of Medicine.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are eager to expand our immunotherapy research in breast cancer through this collaboration with OncoSec. We have previously demonstrated, in a variety of breast cancer models, that local delivery of IL-12 stimulates an anti-breast cancer immune response with applicability beyond end-stage cancer. This delivery system has the potential to be a foundational therapeutic in the treatment of early-stage disease," said Dr. Lyerly. "The translational work with TAVOPLUS has been very encouraging and we are excited to explore the potential of OncoSec’s IL-12 plasmid delivery technology to enhance immune responses targeting HER2+ tumors and to elicit superior T-cell and B-cell responses to HER2 in a variety of preclinical breast cancer models."

Under the terms of the agreement, OncoSec will provide its proprietary TAVO (IL-12 plasmids) and its new electroporation generator, APOLLO, using lower voltage and a longer pulse width which greatly increased DNA-plasmid cellular transfection rates, to Duke University’s Center for Applied Therapeutics. Duke University investigators will conduct preclinical studies using plasmid vaccines targeting HER2 in combination with plasmid vaccines and TAVO in a newly developed endogenous mouse model of HER2+ breast cancer. Additionally, Duke investigators will use TAVO with their high-intensity ultrasound tumor ablation models to explore the impact of IL-12 delivery on the development of systemic immunity.